VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
L-NMMA trimethaphan
Preclinical
Small molecule
V
Vanderbilt University
1
Indications
2
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Fibrinolysis
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Fibrinolysis
Preclinical
Completed
Clinical
Trials by Indication
[1]
Fibrinolysis
1 trial
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
Completed
·
V
Vanderbilt University
·
N/A
·
NCT00685945
·
24 enrolled
Chronic Fatigue Syndrome
1 trial
Autonomic Nervous System and Chronic Fatigue Syndrome
Completed
·
V
Vanderbilt University
·
Phase 1
·
NCT00580619
·
170 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for L-NMMA trimethaphan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
L-NMMA trimethaphan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for L-NMMA trimethaphan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Vanderbilt University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
V
Vanderbilt University
Related News